Insider Transactions in Q1 2024 at Cullinan Oncology, Inc. (CGEM)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2024
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+26.66%
|
-
|
|
Feb 22
2024
|
Jeffrey Alan Jones Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+34.49%
|
-
|
|
Feb 22
2024
|
Nadim Ahmed President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+37.08%
|
-
|
|
Feb 22
2024
|
Corrine Savill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+15.56%
|
-
|
|
Feb 22
2024
|
Jacquelyn L Sumer Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+34.69%
|
-
|
|
Feb 22
2024
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+27.19%
|
-
|
|
Feb 01
2024
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
40,000
-19.42%
|
$640,000
$16.18 P/Share
|
|
Feb 01
2024
|
Corrine Savill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+16.26%
|
$160,000
$4.3 P/Share
|
|
Jan 29
2024
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
40,000
-19.42%
|
$560,000
$14.09 P/Share
|
|
Jan 29
2024
|
Corrine Savill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+16.26%
|
$160,000
$4.3 P/Share
|
|
Jan 23
2024
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
21,316
-11.38%
|
$255,792
$12.46 P/Share
|
|
Jan 23
2024
|
Corrine Savill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,316
+10.22%
|
$85,264
$4.3 P/Share
|
|
Jan 22
2024
|
Corrine Savill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
18,684
-5.15%
|
$224,208
$12.1 P/Share
|
|
Jan 22
2024
|
Corrine Savill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,559
+7.31%
|
$58,236
$4.3 P/Share
|